P891: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM).

• Margaret Macro,
• Cyrille Touzeau,
• Clara Mariette,
• Salomon Manier,
• Sabine Brechignac,
• Laure Vincent,
• Benjamin Hebraud,
• Olivier Decaux,
• Samantha Schulmann,
• Caroline Lenoir,
• Pascal Godmer,
• Agathe Farge,
• Laure Peyro Saint Paul,
• Jean-Jacques Parienti,
• Xavier Leleu

Affiliations

Margaret Macro

1 University Of Caen Normandie Hospital Center, IHBN, Caen, France

Cyrille Touzeau

2 University Hospital of Nantes, Nantes, France

Clara Mariette

3 Centre Hospitalier Universitaire de Grenoble, Hematology Department, La Tronche, France

Salomon Manier

4 Hospital Center University De Lille, Lille, France

Sabine Brechignac

5 Avicenne Hospital (AP-HP), Bobigny, France

Laure Vincent

6 Hospital Center University De Montpellier, Montpellier, France

Benjamin Hebraud

7 IUCT Oncopole, Hematology Department, Toulouse, France

Olivier Decaux

8 CHU Rennes - Pontchaillou Hospital, Haematology Department, Rennes, France

Samantha Schulmann

9 U.h.s.i., Vandœuvre-lès-Nancy, France

Caroline Lenoir

10 Bordeaux Nord Aquitaine Polyclinic, Medical Oncology, Bordeaux, France

Pascal Godmer

11 Hospital Center Bretagne Atlantique, Vannes, France

Agathe Farge

12 University Hospital Center of Caen, IHBN, Caen, France

Laure Peyro Saint Paul

13 University Hospital Center of Caen, DRCI, Caen, France

Jean-Jacques Parienti

13 University Hospital Center of Caen, DRCI, Caen, France

Xavier Leleu

14 Poitiers University Hospital, Hematology Department, Poitiers, France